Oxurion NV trading under "OXUR" on NYSE Euronext Brussels
Oxurion NV launches new global website showcasing its comprehensive drug development approach and diverse portfolio of next-generation therapies for back of the eye disease
Leuven, Belgium, 10 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the start of today's trading under "OXUR" on NYSE Euronext Brussels.
Effective today, the launch of a new ticker and website (www.oxurion.com (http://www.oxurion.com/)) coincides with the company's name change and highlights its comprehensive approach and renewed focus on the development of best-in-class therapies for back of the eye disorders.
"In light of our recent developments and rebranding program, the launch of the new website reaffirms our commitment to develop disease-modifying therapies for patients living with disorders affecting the back of the eye," said Patrik De Haes, M.D., CEO of Oxurion. "This comes at an exciting time as we have made great strides with our clinical developments and we look forward to continuing our work to preserve vision for patients around the world by leveraging our deep scientific knowledge of diseases affecting the back of the eye."
END
For further information please contact:
| Oxurion NV Wouter Piepers, Global Head of Corp Coms & Investor relations +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com (mailto:wouter.piepers@oxurion.com) | |
| EU Media - Citigate Dewe Rogerson David Dible/ Sylvie Berrebi Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com | US Media - LifeSci Public Relations Alison Chen +1 646-876-4932 achen@lifescipublicrelations.com (mailto:achen@lifescipublicrelations.com) |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.
Oxurion's clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME); THR-149, a plasma kallikrein inhibitor for the treatment of DME; and THR-687, a pan-RGD integrin antagonist for the treatment of diabetic retinopathy and DME. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.
Oxurion owns the global rights to JETREA (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).
Oxurion is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company. More information is available at www.oxurion.com (http://www.oxurion.com)
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ThromboGenics NV via Globenewswire
